Qenta and Netcetera - securing cashless payments in the CEE region
16.6.2022 18:36:00 EEST | Business Wire | Press release
2022 continues with a dynamic tempo for Swiss payment expert Netcetera. Starting from June, Netcetera stepped into direct collaboration with Qenta Payment CEE, by being a reliable expert provider and enabling its secure 3DS technology for the Austrian payment gateway.
"We have been using Netcetera’s reliable 3DS technology for several years via our partner networks. We have now chosen to collaborate even more closely and are happy to have Netcetera as our direct technology partner. This partnership provides us with access to the latest payments industry innovations and information, as well as reliable, 24/7 support. For us, the decisive factor to work so closely with Netcetera was their deep industry knowledge and the consistency that Netcetera provides to its customers. Their 3DS SaaS product has allowed us to continue our successful legacy of cashless payment protection in the CEE region. We are pleased to continue developing this partnership both today and in the future." Wolfgang Harder-Pachernegg, VP of Payment Products.
Qenta offers its customers an interface for e-commerce payment systems which can be easily integrated into merchants’ payments process chain. This Austrian payment provider has over 20 years of expertise as a provider of both offline and online payment solutions tailored to their customer’s needs. Through the usage of Netcetera’s 3DS SaaS product, Qenta is to continue providing its customers compelling business benefits such as improved conversions, optimized checkout processes, reduced fraud, and protection from fraudulent chargeback liability.
"We are happy to work with Qenta and to jointly push towards progress in our dynamic industry. Our goal is to guarantee secure online payments for the Qenta customers spread around the whole CEE region. Our 3DS server means excellent service availability and supporting the needs of the provider 24/7." stated Petra Paul, Senior Sales Executive Digital Finance at Netcetera.
Netcetera’s acquiring products enable users to process transactions with 3-D Secure protocols and PSD2 SCA exemptions, certified with the biggest card networks and fully compliant with the standards in the payment industry such as PCI – DSS and PCI-3DS.
Netcetera provides continuous upgrades and updates to support all new trends and client requirements in the payment industry. It constantly monitors, tests and reports in order to offer the best consultancy services to its customers on how to overcome challenges, to improve their conversion rates and to secure their overall fintech business.
About Netcetera
Netcetera is a global software company with cutting-edge IT products and individual digital solutions in the areas of secure digital payment, financial technologies, media, transport, healthcare and insurance. More than 500 banks and issuers, and 160,000 merchants rely on the digital payment solutions and globally certified 3-D Secure products of the market leader for payment security. The owner-managed company covers the entire IT lifecycle, from ideation and strategy to implementation and operation. The balanced combination of the latest technologies and proven standards ensures investment security, from large-scale projects to innovative start-ups. Founded in 1996, Netcetera is a holding company with around 800 employees and is headquartered in Zurich, Switzerland, with locations across Europe, Asia, and the Middle East.
Further information: netcetera.com
About QENTA Payment CEE
Expertise from over 20 years as a provider of payment solutions.
QENTA Payment CEE has been offering you the latest technologies in cashless payment processing for more than 20 years and supports you in developing international payment strategies tailored to your sales channels. As an Austrian payment service provider, we accompany you through all phases of your business development. Our payment solutions, offline and online payments, are individually tailored to your needs and thus make the difference in the area of e-payment. Let one of the most experienced payment service providers advise you. Our team is at your side personally, competently and with commitment.
Further information: qenta.com
Additional features:
File: Qenta&Netcetera_en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005727/en/
Contact information
Media contact
Netcetera
Angelika Seiler
Head of Content
angelika.seiler@netcetera.com
+41 44 297 58 09
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom